Lilly shares suffer on earnings miss and reduced forecast
Eli Lilly (NYSE: LLY) underwhelmed with its first-quarter 2021 financial results, sending its share price down by 2% by lunchtime on Tuesday.
The US drugmaker reported revenue of $6.8 billion, 16% higher than in the same quarter last year, but its adjusted earnings, not reported according to generally accepted accounting principles (GAAP), came in at $1.87 per share, missing the FactSet consensus estimate of $2.12 per share.
Lilly also cut its earnings guidance for the full 2021 fiscal year, mainly due to weaker-than-expected sales of COVID-19 antibodies. The company now expects adjusted earnings of between $7.80 and $8, down from its previous estimate of between $7.75 and $8.40. Analysts had expected full-year earnings of $8.24 per share, according to FactSet.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze